ATANTO 125 mg, hard capsule and atanto 80 mg, hard capsule capsule
Active ingredients: Aprepitant
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Hard capsulecapsuleorale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- ATANTO 125 mg, gélule et ATANTO 80 mg, gélule
- Pharmaceutical form
- gélule et gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) polyamide aluminium PVC de 1 gélule blanche et rose de 125 mg et de 2 gélule(s) blanches de 80 mg
- Marketing authorisation holder
- ZYDUS FRANCE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 27 Sept 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69692800CIP73016887CIP133400930168875Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| APRÉPITANTgélule blanche | 80 mg · une gélule de 80 mg | SA |
| APRÉPITANTgélule rose et blanche | 125 mg · une gélule de 125 mg | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.